Boltz launched as a public benefit corporation out of MIT CSAIL with a $28 million seed round led by Amplify, a16z and Zetta, aiming to make high‑accuracy AI models and drug‑design tools broadly available. Founding models (Boltz‑1/2, BoltzGen) claim AlphaFold‑3‑level structure prediction, binding affinity estimation and modality‑agnostic molecule design. Boltz unveiled Boltz Lab and early discovery agents and positioned itself as an open‑science alternative to closed proprietary stacks, emphasizing wide adoption over single‑asset bets. The company’s model and seed backing mark a notable entrant in the AI‑for‑biology infrastructure space.